Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01543
|
|||||
| Drug Name |
Pazufloxacin
|
|||||
| Synonyms |
Pazufloxacin; T-3761; Pazufloxacin [INN]; UNII-4CZ1R38NDI; CCRIS 7312; T 3761; 4CZ1R38NDI; C16H15FN2O4; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; SMR000466380; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
|
|||||
| Indication | Bacterial conjunctivitis [ICD11: 9A60] | Phase 3 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H15FN2O4
|
|||||
| Canonical SMILES |
CC1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O
|
|||||
| InChI |
InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
|
|||||
| InChIKey |
XAGMUUZPGZWTRP-ZETCQYMHSA-N
|
|||||
| CAS Number |
CAS 127045-41-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 318.3 | Topological Polar Surface Area | 92.9 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
-0.8
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:94700
|
|||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT03696342) Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. | |||||
| 2 | Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats. Eur J Pharmacol. 2004 Oct 6;501(1-3):151-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.